NDAINTRAVENOUSSOLUTION
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
injection, gadofosveset binds reversibly to endogenous serum albumin resulting in longer vascular residence time than non-protein binding contrast agents. The binding to serum albumin also increases the magnetic resonance relaxivity of gadofosveset and decreases the relaxation time (T1) of water…
Clinical Trials (2)
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
Started Aug 2011
Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
Started Jul 2011